Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Quarterly results

Sienna Biopharmaceuticals, Inc. (SNNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2020 SC 13G/A FMR LLC reports a 13.9% stake in SIENNA BIOPHARMACEUTICALS INC
02/05/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
12/17/2019 EFFECT Form EFFECT - Notice of Effectiveness:
12/11/2019 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
12/11/2019 POS AM Form POS AM - Post-Effective amendments for registration statement:
12/11/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/11/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/11/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/11/2019 8-K Quarterly results
11/15/2019 8-K Quarterly results
11/14/2019 GN Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
11/12/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/17/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Notice of Final Order (I) Establishing Notice and Hearing Procedures for Trading of Sienna Equity Securities and (II) Granting Related Relief"
10/04/2019 4 Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 2,396 shares @ $0.23, valued at $551.1
09/23/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Notice of Order"
09/17/2019 8-K Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation unde...
08/08/2019 4 Andrews Timothy K. (General Counsel & Secretary) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 50,000 shares @ $0
Disposed/sold 60,000 options to buy @ $15.08, valued at $904.8k
Disposed/sold 8,518 options to buy @ $15, valued at $127.8k
Disposed/sold 18,290 options to buy @ $2.32, valued at $42.4k
Disposed/sold 22,500 options to buy @ $2.32, valued at $52.2k
Granted 8,518 options to buy @ $0.71, valued at $6k
Granted 60,000 options to buy @ $0.71, valued at $42.6k
Granted 18,290 options to buy @ $0.71, valued at $13k
Granted 22,500 options to buy @ $0.71, valued at $16k
08/08/2019 4 Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 70,000 shares @ $0
Disposed/sold 25,000 options to buy @ $20.19, valued at $504.8k
Disposed/sold 5,600 options to buy @ $15.08, valued at $84.4k
Disposed/sold 20,000 options to buy @ $2.37, valued at $47.4k
Disposed/sold 8,750 options to buy @ $2.32, valued at $20.3k
Granted 25,000 options to buy @ $0.71, valued at $17.8k
Granted 5,600 options to buy @ $0.71, valued at $4k
Granted 8,750 options to buy @ $0.71, valued at $6.2k
Granted 20,000 options to buy @ $0.71, valued at $14.2k
08/08/2019 4 Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 55,000 shares @ $0
Disposed/sold 48,720 options to buy @ $15.08, valued at $734.7k
Disposed/sold 11,926 options to buy @ $15, valued at $178.9k
Disposed/sold 14,904 options to buy @ $2.32, valued at $34.6k
Disposed/sold 22,500 options to buy @ $2.32, valued at $52.2k
Granted 11,926 options to buy @ $0.71, valued at $8.5k
Granted 48,720 options to buy @ $0.71, valued at $34.6k
Granted 14,904 options to buy @ $0.71, valued at $10.6k
Granted 22,500 options to buy @ $0.71, valued at $16k
08/08/2019 4 Beddingfield III Frederick (President & CEO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 150,000 shares @ $0
Disposed/sold 190,910 options to buy @ $15.08, valued at $2.9M
Disposed/sold 42,590 options to buy @ $15, valued at $638.9k
Disposed/sold 40,968 options to buy @ $2.32, valued at $95k
Disposed/sold 93,750 options to buy @ $2.32, valued at $217.5k
Granted 42,590 options to buy @ $0.71, valued at $30.2k
Granted 190,910 options to buy @ $0.71, valued at $135.5k
Granted 40,968 options to buy @ $0.71, valued at $29.1k
Granted 93,750 options to buy @ $0.71, valued at $66.6k
08/08/2019 10-Q Quarterly Report for the period ended June 30, 2019
07/03/2019 4 Stroehmann Diane (See Remarks) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 4,095 shares @ $0.76, valued at $3.1k
07/03/2019 4 Andrews Timothy K. (General Counsel & Secretary) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 4,095 shares @ $0.76, valued at $3.1k
07/03/2019 4 Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 4,095 shares @ $0.76, valued at $3.1k
07/03/2019 4 Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 1,552 shares @ $0.76, valued at $1.2k
07/03/2019 4 Beddingfield III Frederick (President & CEO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Paid exercise price by delivering 17,063 shares @ $0.76, valued at $13k
06/20/2019 GN Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
06/10/2019 GN Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
06/03/2019 4 Burow Kristina (10% Owner) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $1.22, valued at $30.5k
06/03/2019 4 MORE ROBERT J (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $1.22, valued at $30.5k
06/03/2019 4 Leonard Keith R (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $1.22, valued at $30.5k
06/03/2019 4 Hindman James M. (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $1.22, valued at $30.5k
06/03/2019 4 Harris Todd (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $1.22, valued at $30.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy